|
|
Blood, 1 June 2005, Vol. 105, No. 11, pp. 4247-4254.
Prepublished online as a Blood First Edition Paper on February 22, 2005; DOI 10.1182/blood-2004-11-4564.
 Previous Article | Table of Contents | Next Article 
GENE THERAPY
An inducible caspase 9 safety switch for T-cell therapy
Karin C. Straathof,
Martin A. Pulè,
Patricia Yotnda,
Gianpietro Dotti,
Elio F. Vanin,
Malcolm K. Brenner,
Helen E. Heslop,
David M. Spencer, and
Cliona M. Rooney
From the Center for Cell and Gene Therapy; the Departments of Pediatrics, Medicine, Immunology, and Molecular Virology and Microbiology, Baylor College of Medicine; the Methodist Hospital; and Texas Children's Hospital, Houston, TX.
The efficacy of adoptive T-cell therapy as treatment for malignancies may be enhanced by genetic modification of infused cells. However, oncogenic events due to vector/transgene integration, and toxicities due to the infused cells themselves, have tempered enthusiasm. A safe and efficient means of removing aberrant cells in vivo would ameliorate these concerns. We describe a "safety switch" that can be stably and efficiently expressed in human T cells without impairing phenotype, function, or antigen specificity. This reagent is based on a modified human caspase 9 fused to a human FK506 binding protein (FKBP) to allow conditional dimerization using a small molecule pharmaceutical. A single 10-nM dose of synthetic dimerizer drug induces apoptosis in 99% of transduced cells selected for high transgene expression in vitro and in vivo. This system has several advantages over currently available suicide genes. First, it consists of human gene products with low potential immunogenicity. Second, administration of dimerizer drug has no effects other than the selective elimination of transduced T cells. Third, inducible caspase 9 maintains function in T cells overexpressing antiapoptotic molecules. These characteristics favor incorporation of inducible caspase 9 as a safety feature in human T-cell therapies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. A. de Witte, A. Jorritsma, E. Swart, K. C. Straathof, K. de Punder, J. B. A. G. Haanen, C. M. Rooney, and T. N. M. Schumacher
An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease
J. Immunol.,
May 1, 2008;
180(9):
6365 - 6373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kieback, J. Charo, D. Sommermeyer, T. Blankenstein, and W. Uckert
A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer
PNAS,
January 15, 2008;
105(2):
623 - 628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Deschamps, P. Mercier-Lethondal, J. M. Certoux, C. Henry, B. Lioure, C. Pagneux, J. Y. Cahn, E. Deconinck, E. Robinet, P. Tiberghien, et al.
Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft
Blood,
December 1, 2007;
110(12):
3842 - 3852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Quintarelli, J. F. Vera, B. Savoldo, G. M. P. Giordano Attianese, M. Pule, A. E. Foster, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
Blood,
October 15, 2007;
110(8):
2793 - 2802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ahmed, M. Ratnayake, B. Savoldo, L. Perlaky, G. Dotti, W. S. Wels, M. B. Bhattacharjee, R. J. Gilbertson, H. D. Shine, H. L. Weiss, et al.
Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells
Cancer Res.,
June 15, 2007;
67(12):
5957 - 5964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Traversari, S. Marktel, Z. Magnani, P. Mangia, V. Russo, F. Ciceri, C. Bonini, and C. Bordignon
The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies
Blood,
June 1, 2007;
109(11):
4708 - 4715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Biagi, V. Marin, G. M. P. Giordano Attianese, E. Dander, G. D'Amico, and A. Biondi
Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies
Haematologica,
March 1, 2007;
92(3):
381 - 388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, et al.
T lymphocytes redirected against the {kappa} light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
Blood,
December 1, 2006;
108(12):
3890 - 3897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Zhang, A. Barber, and C. L. Sentman
Generation of Antitumor Responses by Genetic Modification of Primary Human T Cells with a Chimeric NKG2D Receptor
Cancer Res.,
June 1, 2006;
66(11):
5927 - 5933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Heslop
Suicide is painless
Blood,
March 15, 2006;
107(6):
2211 - 2212.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Berger, M. E. Flowers, E. H. Warren, and S. R. Riddell
Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation
Blood,
March 15, 2006;
107(6):
2294 - 2302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bondanza, V. Valtolina, Z. Magnani, M. Ponzoni, K. Fleischhauer, M. Bonyhadi, C. Traversari, F. Sanvito, S. Toma, M. Radrizzani, et al.
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes
Blood,
March 1, 2006;
107(5):
1828 - 1836.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
